Clinical Trial

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Study acronym: GALOCEAN
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To describe the effectiveness, treatment patterns, quality of life, and safety of participants with moderately or severely active UC treated with filgotinib in a real-world setting.
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2023-04-05; most recent amendment 2025-12-18.
Status change: Recruiting → Active, Not Recruiting 2025-08-19
Status change: Not Yet Recruiting → Recruiting 2023-05-04
Trial Details
NCT Number NCT05817942
Lead Sponsor Alfasigma S.p.A.
Conditions Ulcerative Colitis
Enrollment 509 participants
Start Date 2023-06-12
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-24